You are here

  • Home
  • Archive
  • Volume 16, Issue 6
  • In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding
  1. Renato D Lopes1,
  2. David A Garcia2
  1. 1Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA
  2. 2Hematology/Oncology, University of New Mexico, Albuquerque, New Mexico, USA
  1. Correspondence to: Renato D Lopes
    Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 0311, Durham, NC 27705, USA; renato.lopes{at}duke.edu

https://doi.org/10.1136/ebm.2011.0023

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17.OpenUrlCrossRefPubMedWeb of Science

    Context

    Atrial fibrillation (AF) is a common dysrhythmia associated with reduced quality of life, higher risk of developing heart failure, cognitive impairment and increased mortality.1,–,3 Patients with AF have a five-fold increased risk of stroke, and up to 25% of all strokes in the elderly are a consequence of AF.4 Vitamin K antagonists (VKAs) reduce the risk of stroke in patients with AF by 64% compared with placebo.5 Unfortunately, many patients at risk for AF-related stroke do not take VKA for a variety of reasons.6,–,8 Aspirin is an alternative antithrombotic strategy which is less effective than VKA but probably more effective than …

    View Full Text

    Footnotes

    • Competing interests RDL and DAG are members of the ARISTOTLE trial's Steering Committee.